Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
11
CVM Quote, Financials, Valuation and Earnings
Last price:
$3.86
Seasonality move
:
9.34%
Day range:
$4.10 - $4.70
52-week range:
$1.98 - $13.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.22x
Volume:
107.4K
Avg. volume:
67.5K
1-year change:
-56.92%
Market cap:
$35.8M
Revenue:
--
EPS (TTM):
-$2.89
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$230.8M | -$0.37 | -87.74% | -73.49% | $81.36 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVM
CEL-SCI Corp.
|
$4.26 | $42.50 | $35.8M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $120.4M | -- | $0.00 | 0% | 0.84x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$63.27 | $81.36 | $8.9B | 41.13x | $0.00 | 0% | 7.97x |
|
SVRA
Savara, Inc.
|
$6.02 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVM
CEL-SCI Corp.
|
44.98% | 0.969 | 20.59% | 1.25x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 3.931 | 7.54% | 3.27x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVM
CEL-SCI Corp.
|
-$964.4K | -$5.4M | -115.01% | -222.8% | -- | -$4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
CEL-SCI Corp. vs. Competitors
-
Which has Higher Returns CVM or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of 96.33%. CEL-SCI Corp.'s return on equity of -222.8% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital CVMCEL-SCI Corp.-- -$0.68 $20.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About CVM or ACAD?
CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 897.65%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that CEL-SCI Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVMCEL-SCI Corp.1 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is CVM or ACAD More Risky?
CEL-SCI Corp. has a beta of 0.854, which suggesting that the stock is 14.59% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock CVM or ACAD?
CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVM or ACAD?
CEL-SCI Corp. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. CEL-SCI Corp.'s net income of -$5.5M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVMCEL-SCI Corp.-- -- -- -$5.5M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns CVM or AGEN?
Agenus, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of -116.82%. CEL-SCI Corp.'s return on equity of -222.8% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CVMCEL-SCI Corp.-- -$0.68 $20.2M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About CVM or AGEN?
CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 897.65%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that CEL-SCI Corp. has higher upside potential than Agenus, Inc., analysts believe CEL-SCI Corp. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVMCEL-SCI Corp.1 0 0 AGENAgenus, Inc.2 1 0 -
Is CVM or AGEN More Risky?
CEL-SCI Corp. has a beta of 0.854, which suggesting that the stock is 14.59% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock CVM or AGEN?
CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVM or AGEN?
CEL-SCI Corp. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. CEL-SCI Corp.'s net income of -$5.5M is lower than Agenus, Inc.'s net income of $63.9M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVMCEL-SCI Corp.-- -- -- -$5.5M AGENAgenus, Inc.0.84x -- $30.2M $63.9M
-
Which has Higher Returns CVM or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of 16.99%. CEL-SCI Corp.'s return on equity of -222.8% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital CVMCEL-SCI Corp.-- -$0.68 $20.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About CVM or ALNY?
CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 897.65%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that CEL-SCI Corp. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVMCEL-SCI Corp.1 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is CVM or ALNY More Risky?
CEL-SCI Corp. has a beta of 0.854, which suggesting that the stock is 14.59% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock CVM or ALNY?
CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVM or ALNY?
CEL-SCI Corp. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. CEL-SCI Corp.'s net income of -$5.5M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVMCEL-SCI Corp.-- -- -- -$5.5M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns CVM or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of 10.7%. CEL-SCI Corp.'s return on equity of -222.8% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital CVMCEL-SCI Corp.-- -$0.68 $20.2M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About CVM or ARWR?
CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 897.65%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.36 which suggests that it could grow by 28.6%. Given that CEL-SCI Corp. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVMCEL-SCI Corp.1 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 3 0 -
Is CVM or ARWR More Risky?
CEL-SCI Corp. has a beta of 0.854, which suggesting that the stock is 14.59% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.681%.
-
Which is a Better Dividend Stock CVM or ARWR?
CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVM or ARWR?
CEL-SCI Corp. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. CEL-SCI Corp.'s net income of -$5.5M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 41.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus 7.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVMCEL-SCI Corp.-- -- -- -$5.5M ARWRArrowhead Pharmaceuticals, Inc.7.97x 41.13x $264M $28.2M
-
Which has Higher Returns CVM or SVRA?
Savara, Inc. has a net margin of -- compared to CEL-SCI Corp.'s net margin of --. CEL-SCI Corp.'s return on equity of -222.8% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital CVMCEL-SCI Corp.-- -$0.68 $20.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About CVM or SVRA?
CEL-SCI Corp. has a consensus price target of $42.50, signalling upside risk potential of 897.65%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that CEL-SCI Corp. has higher upside potential than Savara, Inc., analysts believe CEL-SCI Corp. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVMCEL-SCI Corp.1 0 0 SVRASavara, Inc.6 0 0 -
Is CVM or SVRA More Risky?
CEL-SCI Corp. has a beta of 0.854, which suggesting that the stock is 14.59% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock CVM or SVRA?
CEL-SCI Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI Corp. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVM or SVRA?
CEL-SCI Corp. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. CEL-SCI Corp.'s net income of -$5.5M is higher than Savara, Inc.'s net income of -$29.6M. Notably, CEL-SCI Corp.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI Corp. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVMCEL-SCI Corp.-- -- -- -$5.5M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
